Stephens Cuts Definitive Healthcare (NASDAQ:DH) Price Target to $2.00

Definitive Healthcare (NASDAQ:DH) had its target price decreased by stock analysts at Stephens from $3.00 to $2.00 in a research report issued on Friday,Benzinga reports. The brokerage currently has an “equal weight” rating on the stock. Stephens’ price target indicates a potential upside of 68.49% from the company’s current price.

Several other equities analysts also recently weighed in on DH. Barclays dropped their target price on shares of Definitive Healthcare from $3.00 to $2.75 and set an “underweight” rating for the company in a report on Monday, December 8th. Wall Street Zen downgraded Definitive Healthcare from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 28th. Weiss Ratings restated a “sell (d-)” rating on shares of Definitive Healthcare in a research report on Wednesday, January 21st. Morgan Stanley reiterated an “underperform” rating and set a $3.50 price objective on shares of Definitive Healthcare in a research report on Thursday, December 18th. Finally, Canaccord Genuity Group cut their target price on shares of Definitive Healthcare from $5.00 to $4.00 and set a “hold” rating for the company in a research note on Monday, November 10th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, four have assigned a Hold rating and three have issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $3.66.

Definitive Healthcare Price Performance

DH traded down $0.21 during trading on Friday, reaching $1.19. 240,918 shares of the stock were exchanged, compared to its average volume of 369,506. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.60 and a quick ratio of 1.60. The company has a market capitalization of $167.79 million, a price-to-earnings ratio of -0.72 and a beta of 1.59. Definitive Healthcare has a 1 year low of $1.14 and a 1 year high of $4.70. The business’s 50 day moving average price is $2.21 and its two-hundred day moving average price is $2.89.

Institutional Investors Weigh In On Definitive Healthcare

Several hedge funds have recently modified their holdings of the stock. Goldman Sachs Group Inc. increased its position in Definitive Healthcare by 564.2% during the first quarter. Goldman Sachs Group Inc. now owns 8,716,725 shares of the company’s stock worth $25,191,000 after purchasing an additional 7,404,363 shares during the last quarter. Dimensional Fund Advisors LP raised its position in shares of Definitive Healthcare by 1.6% in the 3rd quarter. Dimensional Fund Advisors LP now owns 2,073,197 shares of the company’s stock worth $8,417,000 after buying an additional 33,612 shares during the period. Arrowstreet Capital Limited Partnership boosted its holdings in Definitive Healthcare by 11.7% in the third quarter. Arrowstreet Capital Limited Partnership now owns 1,216,007 shares of the company’s stock valued at $4,937,000 after acquiring an additional 127,055 shares during the last quarter. Bank of America Corp DE grew its position in Definitive Healthcare by 23.7% during the second quarter. Bank of America Corp DE now owns 769,397 shares of the company’s stock valued at $3,001,000 after acquiring an additional 147,599 shares during the period. Finally, New York State Common Retirement Fund increased its stake in Definitive Healthcare by 0.4% during the second quarter. New York State Common Retirement Fund now owns 766,433 shares of the company’s stock worth $2,989,000 after acquiring an additional 3,066 shares during the last quarter. 98.67% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Definitive Healthcare

Here are the key news stories impacting Definitive Healthcare this week:

• Positive Sentiment: Balance-sheet improvement — cash and cash equivalents rose to ~$163.6M (up ~55% YoY) and total liabilities fell materially, which supports liquidity and runway. Read More.
• Neutral Sentiment: Revenue was roughly in line with forecasts — Q4 revenue reported at ~$61.5M, slightly above consensus, and adjusted EPS of $0.06 matched analysts’ estimates. This limited upside from the print itself. Read More.
• Neutral Sentiment: Analyst sentiment remains muted — brokerages’ average recommendation is “Hold,” implying limited near-term analyst-driven upside. Read More.
• Negative Sentiment: Guidance cut — management lowered Q1 and FY2026 guidance (Q1 EPS guide ~ $0.03 vs. ~$0.05 consensus; FY EPS guide $0.14–$0.17 vs. ~$0.21 consensus; revenue ranges also below Street), which is the principal driver of the stock’s weakness. Read More.
• Negative Sentiment: GAAP profitability and operating cash flow concerns plus institutional selling — reports show a wider operating loss, a GAAP net loss/diluted EPS weakness (reported by third parties) and a sharp drop in cash from operations; several large institutional holders trimmed positions. These factors amplify downside risk. Read More.

Definitive Healthcare Company Profile

Definitive Healthcare (NASDAQ:DH) is a leading provider of intelligence and analytics on healthcare providers, organizations and the professionals who treat patients. Through its cloud-based platform, the company aggregates data from multiple sources—including claims, government registries, commercial filings and proprietary research—to deliver a unified view of the healthcare landscape. Its solutions enable life sciences companies, healthcare providers, payers and consulting firms to identify market opportunities, optimize sales and marketing efforts, improve operational efficiency and support better patient outcomes.

The company’s flagship offering is a subscription-based data platform that features detailed profiles on physicians, hospitals, health systems and post-acute care facilities.